Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?

@article{Morren2010WhereID,
  title={Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?},
  author={John Anthony Morren and N{\'e}stor G{\'a}lvez-Jim{\'e}nez},
  journal={Expert Opinion on Pharmacotherapy},
  year={2010},
  volume={11},
  pages={3085 - 3093}
}
  • John Anthony Morren, Néstor Gálvez-Jiménez
  • Published 2010
  • Medicine
  • Expert Opinion on Pharmacotherapy
  • Importance of the field: Migraine affects approximately 18% of women and 6% of men, and has an immense impact on quality of life and productivity. Advancement in therapeutic options has been slow. For many patients with difficult-to-treat migraine, the appropriate use of dihydroergotamine mesylate (DHE) can result in treatment success and unprecedented patient satisfaction. Areas covered in this review: Migraine treatment guidelines regarding the role of DHE are highlighted. An overview of the… CONTINUE READING

    Topics from this paper.

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 23 CITATIONS

    MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Intravenous Dihydroergotamine Therapy for Pediatric Abdominal Migraines

    VIEW 6 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Dihydroergotamine mesylate‐loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy

    Development and in vitro/in vivo evaluation of dihydroergotamine mesylate loaded maltodextrin-pullulan sublingual films

    VIEW 1 EXCERPT
    CITES BACKGROUND

    A Neurologist’s Guide to Acute Migraine Therapy in the Emergency Room

    VIEW 2 EXCERPTS
    CITES METHODS & BACKGROUND

    FILTER CITATIONS BY YEAR

    2012
    2019

    CITATION STATISTICS

    • 1 Highly Influenced Citations

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 49 REFERENCES